Sangamo Therapeutics, Inc.’s Price-to-Book Ratio at a glance
Sangamo Therapeutics, Inc. reports price-to-book ratio of 9x for Dec 2024. The prior period recorded 1.1x (Dec 2023). Year over year the metric moved +7.89 (+690.2%). The rolling three-period average stands at 3.9x. Data last refreshed Dec 7, 2025, 2:53 AM.
Latest reading
9x · Dec 2024
YoY movement
+7.89 (+690.2%)
Rolling average
3.9x
Current Price-to-Book Ratio
9x
+7.89
+690.2%
Rolling average
3.9x
Latest Value
9x
Dec 2024
YoY Change
+7.89
Absolute
YoY Change %
+690.2%
Rate of change
3-Period Avg
3.9x
Smoothed
Narrative signal
Sangamo Therapeutics, Inc.’s price-to-book ratio stands at 9x for Dec 2024. Year-over-year, the metric shifted by +7.89, translating into a +690.2% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-book ratio shapes Sangamo Therapeutics, Inc.'s story
As of Dec 2024, Sangamo Therapeutics, Inc. reports price-to-book ratio of 9x. Monitor price-to-book trends to gauge how investors value tangible assets and equity on the balance sheet.
Capital-intensive industries
Banks, insurers, and industrials rely on P/B to judge returns on equity relative to book value.
Reading discount or premium
Ratios below 1.0 signal the market values equity below book, which could mean undervaluation or weak profitability.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
100%
Operating Margin
-179.9%
Net Profit Margin
-169.4%
Return on Equity
-430.1%
Return on Assets
-96.4%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Sangamo Therapeutics, Inc. (SGMO) FAQs
Answers tailored to Sangamo Therapeutics, Inc.’s price-to-book ratio profile using the latest Financial Modeling Prep data.
What is Sangamo Therapeutics, Inc.'s current price-to-book ratio?
As of Dec 2024, Sangamo Therapeutics, Inc. reports price-to-book ratio of 9x. This reading reflects the latest filings and price data for SGMO.
How is Sangamo Therapeutics, Inc.'s price-to-book ratio trending year over year?
Year-over-year, the figure shifts by +7.89 (+690.2%). Pair this context with revenue growth and free cash flow signals to gauge momentum for SGMO.
Why does price-to-book ratio matter for Sangamo Therapeutics, Inc.?
Price-to-book compares market value with book value of equity, highlighting balance sheet-driven valuation. For Sangamo Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Sangamo Therapeutics, Inc.'s price-to-book ratio above its recent average?
Sangamo Therapeutics, Inc.'s rolling three-period average sits at 3.9x. Comparing the latest reading of 9x to that baseline highlights whether momentum is building or fading for SGMO.
How frequently is Sangamo Therapeutics, Inc.'s price-to-book ratio refreshed?
Data for SGMO was last refreshed on Dec 7, 2025, 2:53 AM and updates automatically every 24 hours, keeping your valuation inputs current.